Information placed on this digital platform is not intended as a substitute for consultation with your healthcare professional. Please consult your healthcare professional for further information
Entocort® (budesonide) is a first-line anti-inflammatory agent and locally acting glucocorticosteroid and is indicated as follows:
Crohn’s disease: Entocort CR Capsules are indicated for the induction of remission in patients with mild to moderate Crohn’s disease affecting the ileum and/or the ascending colon. Active microscopic colitis: Entocort CR Capsules are indicated for the induction of remission in patients with active microscopic colitis. Entocort CR Capsules are indicated for the maintenance treatment of severe, recurrent microscopic colitis.
Important information on Entocort® and its use can be found in the Summary of Product Characteristics (SPC and PIL). These are meant for HCPs or patients in Ireland who have already been prescribed the product.
Last update: November 2023
All trademarks used or mentioned here are protected by law. Tillotts Pharma AG’s trademarks include Tillotts®, Asacol™, Octasa™, Fivasa™, Lixacol™, Asacolon™, Colpermin™, VistaPrep™, Entocort™, Entocir™, Entocord™, Budecol™ and DIFICLIR™ are either registered or applied for in around 65 countries. The rights to Entocort, including the rights to the trademark, are owned by Tillotts in various countries (transfer of market authorisations to Tillotts in process) except for the USA.
Product information on this website is limited, with the aim of providing a summary for general information purposes for HCPs and patients regarding the activities of Tillotts, and could contain product details or information not accessible or valid in your country. Tillotts disclaims responsibility for access of information which may not comply with any regulation or standard in any particular country. More information may be available from local regulatory authorities, but not all products are available in each country. Please consult a healthcare professional for further information.